Previous 10 | Next 10 |
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, tod...
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, toda...
Shares of micro-cap clinical-stage biotech Pieris Pharmaceuticals ( NASDAQ: PIRS ) have lost 7.4% to $1.69 in Thursday mid-day trading, after the company reported Q2 results that missed estimates and said it would discontinue a phase 2 trial. PIRS posted Q2 GAAP EP...
Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): Q2 GAAP EPS of -$0.14 misses by $0.03 . Revenue of $3.7M (+12.5% Y/Y) misses by $6.77M . Cash, equivalents, and investments totaled $80.9 million for the quarter ended June 30, 2022, compared to a cash and ...
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT Adjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23 Cinrebafusp alfa (PRS-343) demonstrating clinical benefit in HER2-expressing ga...
Pieris Pharmaceuticals ( NASDAQ: PIRS ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.20 (+20.0% Y/Y) and the consensus Revenue Estimate is $10.47M (+218.2% Y/Y). Over the last 3 months, EPS ...
ABMD , ABUS , ACIW , ADAP , OTCQX:ADDYY , ADT , AG , AGIO , AHH , APD , APO , APTV , ARW , ATI , AUPH , AUTL , AZEK , BABA , BALL , BALY , OTCPK:BAYZF , BCE , BCRX , BDX , BKI , CBRE , ...
BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today ann...
BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announce...
The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with this event. For further details see: Pieris Pharmaceuticals (PIRS) Investor presentations - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 millio...